PHG vs NEOG vs CV Stock Comparison

Koninklijke Philips, Neogen and CapsoVision Prices as of Nov 3, 2026 Peers: Industry group
1 more company in this comparison (OSUR) Create a free account to keep reading and compare up to 10 companies.
PHG Koninklijke Philips Nv
$28.47 +19.0% 1M +4.6% 1Y
Market cap
$29.42B
P/E
15.4x
Revenue (TTM)
$30.13B
Div. yield
–
Diagnostic Equipment Healthcare
9 wins
NEOG Neogen Corp
$12.10 -0.4% 1M +92.4% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
CV CapsoVision, Inc
$6.70 +8.6% 1M +40.2% 1Y
Market cap
$343.57M
P/E
–
Revenue (TTM)
$13.89M
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

10 decided of 12

Koninklijke Philips leads on 9 of the 12 questions below (Koninklijke Philips 9, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPHGNEOGCVLeader
Larger companyMarket capitalisation $29.42B $2.72B $343.57M PHG
Cheaper on earningsLower P/E, profitable companies only 15.4x -48.5x -11.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.4x 37.8x — PHG
Faster revenue growthRevenue growth, trailing twelve months +53.4% -0.3% +11.0% PHG
More profitableNet margin, trailing twelve months 6.3% -6.3% -214.7% PHG
Better return on capitalReturn on invested capital 12.4% -0.2% — PHG
Less leveragedLower net debt / EBITDA 1.4x 5.4x — PHG
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +4.6% +92.4% +40.2% NEOG
Better 5-year returnAnnualised price return, 5 years -9.6%/yr -22.7%/yr — PHG
Less volatileAnnualised volatility, 1 year 28.5% 55.7% 96.0% PHG
Higher overall scoreMean of the five percentile scores vs peers 80/100 58/100 29/100 PHG

Percentile Scorecard

PHGNEOGCV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPHGNEOGCV
Valuation 98 #6 of 229 72 #65 of 229 10 #206 of 229
Growth 99 #4 of 221 48 #116 of 221 23 #170 of 221
Profitability 92 #17 of 209 62 #80 of 209 22 #163 of 209
Financial Health 36 #155 of 240 49 #123 of 240 77 #56 of 240
Shareholder Returns 78 #33 of 147 61 #58 of 147 14 #126 of 147
Overall 80 58 29
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics
  • CV ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPHGNEOGCVSPY
1 month +19.0%-0.4%+8.6% -2.0%
3 months +7.6%+2.5%-3.5% -2.2%
6 months +7.6%+30.5%-5.1% +4.2%
Year to date +5.1%+73.1%-37.3% +10.6%
1 year +4.6%+92.4%+40.2% +10.4%
3 years +38.5%-23.5%— +73.6%
3 years, per year +11.5%-8.6%— +20.2%
5 years -39.7%-72.5%— +61.6%
5 years, per year -9.6%-22.7%— +10.1%
10 years -2.8%-37.1%— +261.3%
10 years, per year -0.3%-4.5%— +13.7%

Risk

MeasurePHGNEOGCVSPY
Volatility, 1Y 28.5%55.7%96.0% 12.8%
Downside volatility, 1Y 27.8%46.7%88.9% 12.8%
Beta vs S&P 500, 1Y 0.801.430.64 1.00
Return / volatility, 1Y 0.161.660.42 0.81
Max drawdown, 5Y -75.6%-90.6%-67.8% -25.4%
From 52-week high -13.5%-13.4%-53.5% -3.2%
52-week high $32.91$13.98$14.42 $779.14
52-week low $23.81$5.41$4.59 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePHGNEOGCV
P/E now vs peer median 14.2xmedian 28.1x -47.0xmedian 28.1x -11.2xmedian 28.1x
P/S now vs peer median 0.9xmedian 2.9x 3.0xmedian 2.9x 24.1xmedian 2.9x
EV/EBITDA now vs peer median 7.9xmedian 18.0x 29.2xmedian 18.0x -11.2xmedian 18.0x
P/FCF now vs peer median 5.2xmedian 24.8x 53.0xmedian 24.8x -12.0xmedian 24.8x
P/B now vs peer median 2.1xmedian 2.3x 1.3xmedian 2.3x 25.5xmedian 2.3x
PEG now vs peer median 0.20median 0.95 1.68median 0.95 —median 0.95

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPHGNEOGCV
Revenue $30.13B $883.99M $13.89M
Gross profit $16.13B $418.98M $7.07M
Operating income $2.79B -$7.38M -$30.16M
Net income $1.45B -$56.10M -$29.83M
Free cash flow $5.23B $49.80M -$27.89M
R&D $1.99B $19.76M $21.56M
EPS (diluted) $1.98 $-0.26 $-0.60
Cash & equivalents $3.12B $172.00M –
Total debt $9.23B $774.20M –
Shares (diluted) 962.50M 218.10M 49.94M
Enterprise value $17.69B $2.06B $343.57M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPHGNEOGCV
P/E 14.2x -47.0x -11.2x
P/FCF 5.2x 53.0x -12.0x
P/Operating cash flow 7.7x 31.0x -12.0x
P/S 0.9x 3.0x 24.1x
P/B 2.1x 1.3x 25.5x
P/Tangible book 2.7x 3.3x 25.5x
EV/EBITDA 7.9x 29.2x -11.2x
EV/EBIT 12.0x -439.7x -11.1x
EV/Revenue 1.1x 3.7x 24.1x
EV/FCF 6.4x 65.1x -12.0x
EV/Operating cash flow 9.4x 38.0x -12.0x
PEG (3Y EPS CAGR) 0.20 1.68 –

Growth

14 metrics
MetricPHGNEOGCV
Revenue growth (1Y) 53.4% -0.3% 11.0%
Revenue CAGR (3Y) 15.1% -1.3% –
Gross profit growth (1Y) 76.3% 1.8% 5.6%
Gross profit CAGR (3Y) 4.0% -3.1% –
Operating income growth (1Y) 49.6% 99.3% -47.3%
Operating income CAGR (3Y) 337.8% -29.0% –
Net income growth (1Y) 444.3% 94.6% -46.0%
Net income CAGR (3Y) 45.2% -28.3% –
EPS growth (1Y) 177.7% 94.6% 93.3%
EPS CAGR (3Y) 69.9% -28.0% –
Operating cash flow growth (1Y) 154.0% -1.9% -26.6%
Operating cash flow CAGR (3Y) 34.9% 2.9% –
Free cash flow growth (1Y) 74.5% 1,631% -26.5%
Free cash flow CAGR (3Y) 35.7% 126.1% –

Profitability

14 metrics
MetricPHGNEOGCV
Gross margin 53.5% 47.4% 50.9%
EBITDA margin 14.1% 12.5% -215.5%
Operating margin 9.2% -0.8% -217.1%
Pretax margin 8.7% -7.7% -214.6%
Net margin 6.3% -6.3% -214.7%
FCF margin 17.4% 5.6% -200.8%
Operating cash flow margin 11.8% 9.6% -200.3%
Return on equity 13.2% -2.7% -178.7%
Return on assets 5.5% -1.7% -134.0%
Return on invested capital 12.4% -0.2% –
Return on capital employed 12.6% -0.2% -176.4%
Asset turnover 1.0x 0.3x 0.6x
Cash conversion (OCF / net income) 2.4x -1.5x 0.9x
Stock comp / revenue 0.5% 1.3% 10.2%

Financial Health

11 metrics
MetricPHGNEOGCV
Debt / assets 29.0% 23.4% –
Debt / equity 0.7x 0.4x –
Net debt / EBITDA 1.4x 5.4x –
Debt / FCF 1.8x 15.5x –
Liabilities / assets 58.7% 36.8% 29.1%
Equity / assets 41.3% 63.2% 70.9%
Interest coverage 6.5x – –
Current ratio 1.3x 3.9x 3.4x
Quick ratio 0.8x 2.1x –
Cash ratio 0.4x 1.2x –
Altman Z-score – 1.48 20.57

Shareholder Returns

7 metrics
MetricPHGNEOGCV
Dividend yield 3.5% – –
Net buyback yield -0.8% -0.1% -12.1%
Shareholder yield 2.7% -0.1% -12.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPHGNEOGCV
Forward P/E 14.4xFY2026 37.8xFY2026 –
EPS, next fiscal year $1.98FY2026 $0.32FY2026 $-0.58FY2026
EPS growth, next FY +6.5%FY2026 0.0%FY2026 –
EPS growth, the year after -10.1% +31.3% –
Revenue, next fiscal year $21.63BFY2026 $847.28MFY2026 $13.91MFY2026
Revenue growth, next FY +1.8%FY2026 -2.7%FY2026 +2.7%FY2026
Revenue growth, the year after -8.2% -1.5% +46.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPHGNEOGCV
Held by institutions 5.4% 100.0% 10.2%
Institutions holding 365 315 50
Change in shares held, QoQ +0.8% +1.6% +27.6%
Institutions buying 268 151 36
Institutions selling 76 106 8
Buyers to sellers 3.53 1.42 4.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PHGNEOGCV
PHG 1.00 0.32 -0.01
NEOG 0.32 1.00 0.03
CV -0.01 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PHG, NEOG and CV?

Koninklijke Philips (PHG) is the largest by market capitalisation: Koninklijke Philips (PHG) $29.42B, Neogen (NEOG) $2.72B, CapsoVision (CV) $343.57M.

Which company is growing faster?

Koninklijke Philips (PHG) grew revenue fastest over the trailing twelve months: Koninklijke Philips (PHG) +53.4%, Neogen (NEOG) -0.3%, CapsoVision (CV) +11.0%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Koninklijke Philips (PHG) 6.3%, Neogen (NEOG) -6.3%, CapsoVision (CV) -214.7%). On return on invested capital, Koninklijke Philips (PHG) leads (Koninklijke Philips (PHG) 12.4%, Neogen (NEOG) -0.2%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Koninklijke Philips (PHG) +4.6%, Neogen (NEOG) +92.4%, CapsoVision (CV) +40.2%. Over five years, Koninklijke Philips (PHG) compounded fastest (Koninklijke Philips (PHG) -9.6%/yr, Neogen (NEOG) -22.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Koninklijke Philips (PHG) 28.5%, Neogen (NEOG) 55.7%, CapsoVision (CV) 96.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PHG, NEOG and CV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.